Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 3/20 | 0.42 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10109095 | 1.00 | APP (0.50) | APPTDP1SLC5A1SLC5A2TYR | |
| SCHEMBL10102864 | 1.00 | APP (0.50) | APPTDP1SLC5A1SLC5A2TYR | |
| SCHEMBL10102899 | 0.91 | SLC5A1 (0.43) | APPTDP1SLC5A1SLC5A2TYR | |
| SCHEMBL10102861 | 0.91 | SLC5A1 (0.43) | APPTDP1SLC5A1SLC5A2TYR | |
| SCHEMBL10108861 | 0.91 | SLC5A1 (0.43) | APPTDP1SLC5A1SLC5A2TYR | |
| SCHEMBL10108864 | 0.87 | ALDH1A1 (0.49) | TDP1SLC5A1SLC5A2TYRALDH1A1 | |
| SCHEMBL15198140 | 0.87 | ALDH1A1 (0.49) | TDP1SLC5A1SLC5A2TYRALDH1A1 | |
| SCHEMBL10119569 | 0.87 | ALDH1A1 (0.49) | TDP1SLC5A1SLC5A2TYRALDH1A1 | |
| SCHEMBL15198316 | 0.87 | ALDH1A1 (0.49) | TDP1SLC5A1SLC5A2TYRALDH1A1 | |
| SCHEMBL10103013 | 0.86 | APP (0.56) | APPTDP1SLC5A1SLC5A2TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722864-B2 | Glycosylated acetaminophen pro-drug analogs | NuTek Pharma Ltd. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722864-B2 | Glycosylated acetaminophen pro-drug analogs | NuTek Pharma Ltd. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | NuTek Pharma Ltd. | 2013-08-22 | — | — | US | disclosed |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | NuTek Pharma Ltd. | 2013-08-22 | — | — | US | disclosed |
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | UGT1A3, GCG, UGT1A1 | APP 851/4885TDP1 2646/4885SLC5A1 62/4885 |
| US-20130217640-A1 | GLYCOSYLATED ACETAMINOPHEN PRO-DRUG | UGT1A3, GCG, UGGT1 | APP 811/4885TDP1 2617/4885SLC5A1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.